Tinidazole treatment of metronidazole-resistant vaginal trichomoniasis

Treating patients with metronidazole-resistant vaginal trichomoniasis is a significant problem and treatment options are very limited. Although most patients with Trichomonas, who in vitro have decreased sensitivity to metronidazole, respond to treatment with high doses of metronidazole, this treatment is poorly tolerated and ineffective clinical is a common phenomenon.

Scientists from Detroit, Michigan conducted a study on the efficacy of systemic (oral) and topical dosing of tinidazole in the treatment of metronidazole-resistant trichomoniasis. The treatment was effective in 22 (92%) of the 24 patients.

The results of the study, to some extent, surprised the researchers, because these drugs belong to the same therapeutic group - nitroimidazoles.

Therapy included oral tinidazole 500 mg x 4 times daily + intravaginal tinidazole (500 mg x twice daily) for 14 days or tinidazole 1 gx 3 times daily + intravaginal tinidazole 500 mg x 3 times a day also for 14 days.

Treatment with tinidazole has been effective, although previously women with high doses of metronidazole had been prescribed without success. Despite the use of high doses of tinidazole, the tolerability of the drug was good and the number of side effects was minimal. Due to adverse drug reactions, treatment was canceled in one patient.

Thus, reports of trichomonads resistant to metronidazole and limitation of therapeutic possibilities particularly highlight the need to find additional anti-trichomonas drugs.